Skip to main content

Research Repository

Advanced Search

Impact of polymorphic variants on the molecular pharmacology of the two-agonist conformations of the human ?1-adrenoceptor

Baker, Jillian G.; Hill, Stephen J.; Proudman, Richard G.W.


Professor of Drug Discovery and Respiratory Medicine

Stephen J. Hill

Richard G.W. Proudman


?-blockers are widely used to improve symptoms and prolong life in heart disease primarily by inhibiting the actions of endogenous catecholamines at the ?1-adrenoceptor. There are two common naturally occurring polymorphisms within the human ?1-adrenoceptor sequence: Ser or Gly at position 49 in the N-terminus and Gly or Arg at position 389 in the C-terminus and some clinical studies have suggested that expression of certain variants may be associated with disease and affect response to treatment with ?-blockers. The ?1-adrenoceptor also exists in two agonist conformations - a high affinity catecholamine conformation and a low affinity secondary agonist conformation. Receptor-effector coupling and intracellular signalling from the different conformations may be affected by the polymorphic variants.

Here, we examine in detail the molecular pharmacology of the ?1-adrenoceptor polymorphic variants with respect to ligand affinity, efficacy, activation of the different agonist conformations and signal transduction and determine whether the polymorphic variants do indeed affect this secondary conformation. Stable cell lines expressing the wildtype and polymorphic variants were constructed and receptor pharmacology examined using whole cell binding and intracellular secondary messenger techniques.

There was no difference in affinity for agonists and antagonists at the human wildtype ?1-adrenoceptor (Ser49/Gly389) and the polymorphic variants Gly49/Gly389 and Ser49/Arg389. Furthermore, the polymorphic variant receptors both have two active agonist conformations with pharmacological properties similar to the wildtype receptor. Although the polymorphism at position 389 is thought to occur in an intracellular domain important for Gs-coupling, the two agonist conformations of the polymorphic variants stimulate intracellular signalling pathways, including Gs-cAMP intracellular signalling, in a manner very similar to that of the wildtype receptor.


Baker, J. G., Hill, S. J., & Proudman, R. G. (2013). Impact of polymorphic variants on the molecular pharmacology of the two-agonist conformations of the human ?1-adrenoceptor. PLoS ONE, 8(11),

Journal Article Type Article
Publication Date Nov 8, 2013
Deposit Date Mar 24, 2014
Publicly Available Date Mar 24, 2014
Journal PLoS ONE
Electronic ISSN 1932-6203
Publisher Public Library of Science
Peer Reviewed Peer Reviewed
Volume 8
Issue 11
Public URL
Publisher URL


JILLIAN2.pdf (2.3 Mb)

Copyright Statement
Copyright information regarding this work can be found at the following address:

You might also like

Downloadable Citations